Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Chris Noth responds to backlash after seemingly shading 'Sex and the City' costar Sarah Jessica Parker: 'It is not news' - 2Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- 3What to know about Jack Dorsey's new Vine revival, DiVine
- 4Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- 5Top 10 Books That Will Have an impact on Your Viewpoint
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- Choosing the Ideal Bed for Quality Rest and Solace
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- 5 Breakout Stars in Ongoing television Series
- At least 11 killed in South Africa mass shooting
- A NASA spacecraft orbiting Mars may be dead
- Blue Origin's next space tourism flight will break new ground for people with disabilities
- Outer space conditions hamper sperm's ability to navigate toward an egg
